Midostaurin companion diagnostic - Invivoscribe/Novartis

Drug Profile

Midostaurin companion diagnostic - Invivoscribe/Novartis

Alternative Names: FLT3 companion diagnostic; PKC 412 companion diagnostic - Invivoscribe/Novartis

Latest Information Update: 02 Dec 2016

Price : $50

At a glance

  • Originator Takara Bio
  • Developer Invivoscribe Technologies; Novartis
  • Class Diagnostic agents
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Acute myeloid leukaemia

Most Recent Events

  • 14 Nov 2016 Preregistration for Acute myeloid leukaemia (Diagnosis) in European Union (unspecified route)
  • 14 Nov 2016 Preregistration for Acute myeloid leukaemia (Diagnosis) in USA (unspecified route)
  • 15 Feb 2011 Invivoscribe Technologies and Novartis enter into a collaboration to develop and commercialise a midostaurin companion diagnostic
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top